ArriVent's ARR-217 Shows 44.8% Response Rate at 6 mg/kg in Phase 1 Colorectal Cancer Trial

• ArriVent Biopharma reported a 44.8% response rate for ARR-217 at 6 mg/kg in Phase 1 patients with heavily pretreated colorectal cancer.
• The 13 responses included seven confirmed partial responses, four pending confirmation and two unconfirmed partial responses.
• Disease control reached 93.1% among 29 patients receiving 6 mg/kg every three weeks.
• Grade 3 or higher treatment-related adverse events affected 20.4% at that dose; no treatment-related deaths or interstitial lung disease occurred across doses.
• ARR-217 advanced into Phase 1b dose optimization at 5 and 6 mg/kg every three weeks, with further data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-118550), on October 26, 2026, and is solely responsible for the information contained therein.